Ipilimumab/nivolumab-induced pseudolymphoma in a patient with malignant melanoma.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Humans
Ipilimumab
/ administration & dosage
Male
Melanoma
/ drug therapy
Neoplasms, Second Primary
/ drug therapy
Nivolumab
/ administration & dosage
Pseudolymphoma
/ chemically induced
Skin Neoplasms
/ drug therapy
Steroids
/ administration & dosage
Melanoma, Cutaneous Malignant
drug rash
ipilimumab
melanoma
nivolumab
oncodermatology
pseudolymphoma
Journal
Journal of cutaneous pathology
ISSN: 1600-0560
Titre abrégé: J Cutan Pathol
Pays: United States
ID NLM: 0425124
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
22
06
2019
revised:
05
10
2019
accepted:
27
10
2019
pubmed:
5
11
2019
medline:
15
12
2020
entrez:
3
11
2019
Statut:
ppublish
Résumé
Combination therapy with ipilimumab and nivolumab is an adjuvant treatment approach for metastatic melanoma that boasts increased 3-year survival when compared with a single immunotherapy agent. Combination therapy, however, is associated with increased toxicities, especially cutaneous side-effects. Here we present a patient with metastatic melanoma and a sudden eruption of painful nodules on the face and arms 10 days after the administration of the fourth dose of combination ipilimumab/nivolumab. Biopsies demonstrated lymphoid hyperplasia, not clinically or pathologically consistent with an infectious, malignant or autoimmune etiology; a diagnosis of pseudolymphoma secondary to ipilimumab/nivolumab was made. After a steroid taper, the lesions resolved, and the patient was restarted on nivolumab monotherapy 2 weeks later without recurrence of symptoms or disease.
Substances chimiques
Ipilimumab
0
Steroids
0
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-393Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Mitteldorf C, Kempf W. Cutaneous pseudolymphoma. Surg Pathol Clin. 2017;10(2):455-476.
Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol. 1998;38(6):877-895.
Magro CM, Daniels BH, Crowson AN. Drug induced pseudolymphoma. Semin Diagn Pathol. 2018;35(4):247-259.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
Callahan MK, Klugger H, Postow MA, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36(4):391-398.
Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2016;34(15):9505-9505.
De Bock M, Hulstaert E, Kruse V, et al. Psoriasis vulgaris exacerbation during treatment with a PD-1 inhibitor: case report and review of literature. Case Rep Dermatol. 2018;10(2):190-197.
Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol. 2016;43(8):688-696.
Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-384.
Tetzlaff MT, Nelson KC, Diab A, et al. Granulomatous / sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J Immunother Cancer. 2018;6(1):14.
Castillo B, Gibbs J, Brohl AS, Seminario-Vidal L. Checkpoint inhibitor-associated cutaneous small vessel vasculitis. J Am Acad Dermatol Case Rep. 2018;4(7):675-677.
Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases. Melanoma Res. 2019;29(3):338-341.
Bergman R. Pseudolymphoma and cutaneous lymphoma: facts and controversies. Clin Dermatol. 2010;28(5):568-574.
Hofmann L, Forschner A, Loquai C, et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:190-209.
Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125-128.
Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932-1946.